Abstract A28: Mechanistic study involving the combined antiproliferative effect of Etoricoxib- cyclooxygenase-2 inhibitor and cholecystokinin-2 receptor antagonist in human pancreatic cancer cells

Conclusion: The combined effect of Cyclooxygenase-2 inhibitor and Cholecystokinin-2 Receptor antagonists was calculated using Chaou Tatlay method. A combination index was calculated. As a class NSAIDs possess analgesic, antipyretic, anti-inflammatory, and there is persuasive evidence that COX-2 inhibitor suppress cancer cell proliferation owing to their role in apoptosis, compelling evidence suggest that COX-2 over-expression promotes whereas COX-2 inhibition prevents tumor initiation and promotions. NSAIDs and COX-2 selective inhibitors may have different effects on cancer may be stage dependent therefore a better understanding of the critical COX related mechanisms of carcinogenesis, proliferation, apoptosis, inflammation, angiogenesis and tumor invasion will help to define the potential of COX-2 blockage in cancer therapy. Previous studies have shown that NSAIDs and specific COX-2 inhibitors are able to enhance the effect of certain cystostaic agents, a specific COX-2 inhibitor Celecoxib enhances the cystostaic effect of doxorubicin on tumor cell lines (Wijnggaarden J.V. et.al. 2007). Results in our lab showed that combination of doxorubicin and etoricoxib synergistically inhibited the proliferation of Hela and Miapaca cell lines. These results has indicated that the combination therapy of COX-2 selective inhibitors may be the potential chemotherapeutic strategy for cancer prevention. In the present study, human pancreatic cancer cell lines, in which the CCK-2 receptor and...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Managing G2/M Control: Poster Presentations - Proffered Abstracts Source Type: research